Renazorb (SPI-014)

Renazorb (SPI-014)

 

A potent and selective second generation lanthanum-based phosphate binding agent utilizing proprietary nanoparticle technology

 

More on Renazorb

Scanning Electron Micrograph (SEM) of SPI-014

Chronic Kidney Disease

According to the National Kidney Foundation, there are an estimated 26 million adults suffering from CKD in the US.1 Of these CKD patients, approximately 400,000 patients are at stage 4 and approximately 660,000 are at Stage 5 (ESRD). The incidence of ESRD is increasing at approximately 6% per year. Approximately 70% of ESRD patients have hyperphosphatemia.

Target Indications
  • Hyperphosphatemia in End Stage Renal Disease (ESRD).
  • Hyperphosphatemia in earlier stages of CKD
Route of Administration
  • Oral tablet
Mode of Action
  • Renazorb binds to phosphates and forms an insoluable lanthanum phosphate complex which is expected to reduce serum phosphate levels in ESRD patients.
Status
  • Phase 2
Reference

1. https://www.kidney.org/news/newsroom/factsheets/FastFacts